Hrt Financial LP Affimed N.V. Transaction History

Hrt Financial LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$0.57 - $1.08 $8,766 - $16,609	15,379 New	15,379 $9,000
Q2 2022 Aug 12, 2022	BUY	$2.27 - $4.86 $94,102 - $201,471	41,455 Added 60.63%	109,828 $304,000
Q1 2022 May 16, 2022	BUY	$3.69 - $5.65 $191,883 - $293,805	52,001 Added 317.62%	68,373 $298,000
Q4 2021 Feb 14, 2022	BUY	$5.37 - $7.07 $87,917 - $115,750	16,372 New	16,372 $90,000
Q2 2018 Aug 15, 2018	SELL	$1.65 - $2.5 $24,812 - $37,595	-15,038 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$1.25 - $2.65 $18,797 - $39,850	15,038 New	15,038 $27,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.